Literature DB >> 12010822

Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.

Leonid S Metelitsa1, Stephen D Gillies, Michael Super, Hiroyuki Shimada, C Patrick Reynolds, Robert C Seeger.   

Abstract

Polymorphonuclear leukocytes (PMNs) mediate antibody-dependent cellular cytotoxicity (ADCC), which is increased by the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF). We sought to determine whether PMN ADCC also would be increased by the addition of an antibody/GM-CSF fusion protein and whether this would be associated with the up-regulation and activation of Mac-1 (CD11b/CD18) and with azurophil granule exocytosis. ADCC against LA-N-1 human neuroblastoma cells was evaluated with 4-hour calcein acetoxymethyl ester (calcein-AM) microcytotoxicity assay, electron microscopy, and multi-parameter flow cytometry. With the calcein-AM assay, LA-N-1 cell survival was 10%, 55%, and 75% when PMN ADCC was mediated by the antidisialoganglioside (anti-GD2) immunocytokine hu14.18/GM-CSF, by monoclonal antibody (mAb) hu14.18 mixed with GM-CSF, and by hu14.18 alone. Function-blocking mAbs demonstrated that FcgammaRII and FcgammaRIII were required for ADCC with hu14.18 alone or mixed with GM-CSF, but that only FcgammaRII was required for ADCC with hu14.18/GM-CSF. ADCC mediated by hu14.18 and hu14.18/GM-CSF was Mac-1 dependent. Electron microscopy demonstrated the greatest PMN adhesion, spreading, and lysis of targets with hu14.18/GM-CSF. Monoclonal antibodies blocking Mac-1 function allowed the tethering of PMN to targets with hu14.18/GM-CSF but prevented adhesion, spreading, and cytolysis. Flow cytometry showed that hu14.18 with or without GM-CSF and hu14.18/GM-CSF all mediated Mac-1-dependent PMN-target cell conjugate formation but that GM-CSF was required for the highest expression and activation of Mac-1, as evidenced by the mAb24-defined beta(2)-integrin activation epitope. Hu14.18/GM-CSF induced the highest sustained azurophil granule exocytosis, almost exclusively in PMNs with activated Mac-1. Thus, hu14.18/GM-CSF facilitates PMN ADCC against neuroblastoma cells associated with FcgammaRII and Mac-1-dependent enhanced adhesion and degranulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010822     DOI: 10.1182/blood.v99.11.4166

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Issues related to targeted delivery of proteins and peptides.

Authors:  Yingjuan Lu; Jun Yang; Emanuela Sega
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

3.  Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors.

Authors:  Markus Gantert; Felicitas Lewrick; Joanna E Adrian; Jochen Rössler; Thomas Steenpass; Rolf Schubert; Regine Peschka-Süss
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

4.  NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.

Authors:  Xin Xu; Wei Huang; Andras Heczey; Daofeng Liu; Linjie Guo; Michael Wood; Jingling Jin; Amy N Courtney; Bin Liu; Erica J Di Pierro; John Hicks; Gabriel A Barragan; Ho Ngai; Yuhui Chen; Barbara Savoldo; Gianpietro Dotti; Leonid S Metelitsa
Journal:  Clin Cancer Res       Date:  2019-09-04       Impact factor: 12.531

5.  Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.

Authors:  Irene Y Cheung; Katharine Hsu; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

Review 6.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

Review 7.  GD2-targeted immunotherapy and radioimmunotherapy.

Authors:  Konstantin Dobrenkov; Nai-Kong V Cheung
Journal:  Semin Oncol       Date:  2014-07-21       Impact factor: 4.929

8.  Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.

Authors:  Hong Xu; Hongfen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2016-05-16       Impact factor: 11.151

Review 9.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

10.  Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.

Authors:  Guosheng Xiong; Mohamed I Husseiny; Liping Song; Anat Erdreich-Epstein; Gregory M Shackleford; Robert C Seeger; Daniela Jäckel; Michael Hensel; Leonid S Metelitsa
Journal:  Int J Cancer       Date:  2010-06-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.